BUZZ-Lexicon Pharma slides after stock offering unveil

Reuters01-30
BUZZ-Lexicon Pharma slides after stock offering unveil

** Shares of Lexicon Pharmaceuticals LXRX.O down 5.6% in extended trading to $1.36 as co seeks equity raise

** Texas-based LXRX commences proposed stock offering; deal size not disclosed

** It also intends to sell stock in private placement to an affiliate of Invus, LP, its largest stockholder, concurrently with the public offering

** Co to use net offering proceeds from the transactions to fund continued R&D of its drug candidates and for working capital and other general purposes

** Jefferies and Piper Sandler joint book runners

** LXRX shares on Jan 21 jumped 19% to close at $1.56 after co said U.S. FDA cleared late‑stage trial of diabetic nerve‑pain drug, pilavapadin

** Shares ended session on Thurs down 4% at $1.44. Stock up 25% to begin the year and up ~74% over the past 12 months

** Co has roughly $550 mln market cap based on ~363.5 mln shares outstanding as of Jan 26, per the prospectus

** 3 of 5 analysts rate the stock "strong buy" or "buy", 2 rate "hold"; median PT $2.10, LSEG data reflects

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment